BOSTON, Nov. 10, 2025 (WORLD NEWSWIRE)– Vor Biopharma Inc. (NASDAQ: VOR), a clinical-stage biotechnology business committed to changing the treatment of autoimmune illness, today revealed the rates of an underwritten public offering of 10,000,000 shares of its typical stock at a public offering cost of $10.00 per share. The gross profits from the offering are anticipated to be $100 million, before subtracting the underwriting discount rates and commissions and offering costs. The offering is anticipated to close on or about November 12, 2025, based on popular closing conditions. In addition, Vor Bio has actually given the underwriters a 30-day alternative to buy approximately an extra 1,500,000 shares of its typical stock at the general public offering cost, less underwriting discount rates and commissions. All of the shares are being offered by Vor Bio.
J.P. Morgan, Jefferies, Citigroup and TD Cowen are functioning as joint book-running supervisors for the offering.
The shares of typical stock explained above are being used by Vor Bio pursuant to a rack registration declaration submitted by Vor Bio with the Securities and Exchange Commission (SEC) that was stated efficient by the SEC on March 31, 2025. The offering is being made just by ways of a prospectus supplement and an accompanying prospectus that form a part of the registration declaration. An initial prospectus supplement and accompanying prospectus associating with the offering were submitted with the SEC and are offered on the SEC’s site situated at http://www.sec.gov. A last prospectus supplement and accompanying prospectus associating with the offering will be submitted with the SEC and will be offered on the SEC’s site situated at http://www.sec.gov. Copies of the last prospectus supplement and the accompanying prospectus associated to this offering, when offered, might be gotten from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Opportunity, Edgewood, NY 11717, or by e-mail at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attention: Equity Distribute Prospectus Department, 520 Madison Opportunity, New York City, NY 10022, by telephone at (877) 821-7388, or by e-mail at Prospectus_Department@Jefferies.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Opportunity, Edgewood, NY 11717 or by means of telephone: (800) 831-9146; or TD Securities (U.S.A.) LLC, 1 Vanderbilt Opportunity, New York City, NY 10017, c/o Broadridge Financial Solutions, 1155 Long Island Opportunity, Edgewood, NY 11717 or by e-mail at TDManualrequest@broadridge.com.
This news release will not make up a deal to offer or a solicitation of a deal to purchase these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such deal, solicitation or sale would be illegal previous to the registration or certification under the securities laws of any such state or other jurisdiction.
About Vor Bio
Vor Bio is a clinical-stage biotechnology business changing the treatment of autoimmune illness. The Business is concentrated on quickly advancing telitacicept, an unique dual-target combination protein, through Stage 3 scientific advancement and prospective commercialization to deal with major autoantibody-driven conditions worldwide.
Forward Looking Declarations
Specific declarations in this news release are positive declarations that include a variety of dangers and unpredictabilities. These declarations might be determined by initial words such as “prepare for,” “think,” “anticipates,” “plans,” “may,” “strategy,” “should,” “based on,” “will,” “would” or words of comparable significance, or by the reality that they do not relate strictly to historic or existing realities. Such positive declarations consist of declarations concerning the timing and conclusion of the offering, the fulfillment of popular closing conditions associated with the offering and the awaited gross profits from the offering. For such declarations, Vor Bio declares the security of the Personal Securities Lawsuits Reform Act of 1995. Real occasions or outcomes might vary materially from Vor Bio’s expectations. Aspects that might trigger real outcomes to vary materially from the positive declarations consist of, however are not restricted to, dangers and unpredictabilities connected with market conditions and the fulfillment of popular closing conditions associated with the proposed offering, and those aspects revealed in Vor Bio’s filings with the SEC, including its Quarterly Report on Kind 10-Q for the quarter ended June 30, 2025. These positive declarations represent Vor Bio’s judgment since the time of this release. Vor Bio disclaims any intent or responsibility to upgrade these positive declarations, aside from as might be needed under appropriate law.
Media & & Financier Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com